DSF/Cu induces antitumor effect against diffuse large B-cell lymphoma through suppressing NF-κB/BCL6 pathways.
Apoptosis
B-cell lymphoma 6
Cell cycle arrest
Diffuse large B-cell lymphoma
Disulfiram
Nuclear factor kappa beta
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
26 Jul 2022
26 Jul 2022
Historique:
received:
04
05
2022
accepted:
08
07
2022
entrez:
26
7
2022
pubmed:
27
7
2022
medline:
27
7
2022
Statut:
epublish
Résumé
The B-cell lymphoma 6 (BCL6) oncogene is required for the survival of diffuse large B-cell lymphoma (DLBCL), which is incurable using conventional chemotherapy. Thus, it is imperative to improve the survival of patients with DLBCL. Disulfide (DSF) has been shown to have anticancer effects, but its effect on DLBCL remains unclear. Four DLBCL cell lines (OCI-LY1, OCI-LY7, OCI-LY10 and U2932) and primary DLBCL cells from eight newly diagnosed DLBCL patients were pretreated with DSF alone or in combination with Cu. Cell morphology was observed under microscope. Flow cytometry was performed to evaluate the cell apoptosis, cell cycle, the mitochondrial membrane potential and the intracellular accumulation of reactive oxygen species (ROS). The protein expression was respectively measured by flow cytometry and western blotting. DSF or DSF/Cu exhibited a marked inhibitory effect on the growth of DLBCL cells, accompanied by cell cycle arrest at the G0/G1 phase. Meanwhile, DSF or DSF/Cu significantly induced DLBCL cells apoptosis. Further study revealed that DSF or DSF/Cu promoted apoptosis by inhibiting NF-κB signaling pathway. Interestingly, DSF/Cu significantly reduced BCL6 and AIP levels. In addition, DSF significantly up-regulate p53 protein in OCI-LY7 and OCI-LY10 while down-regulate p53 protein in OCI-LY1 and U2932. These results provided evidence for the anti-lymphoma effects of DSF on DLBCL and suggested that DSF has therapeutic potential to DLBCL.
Sections du résumé
BACKGROUND
BACKGROUND
The B-cell lymphoma 6 (BCL6) oncogene is required for the survival of diffuse large B-cell lymphoma (DLBCL), which is incurable using conventional chemotherapy. Thus, it is imperative to improve the survival of patients with DLBCL. Disulfide (DSF) has been shown to have anticancer effects, but its effect on DLBCL remains unclear.
METHODS
METHODS
Four DLBCL cell lines (OCI-LY1, OCI-LY7, OCI-LY10 and U2932) and primary DLBCL cells from eight newly diagnosed DLBCL patients were pretreated with DSF alone or in combination with Cu. Cell morphology was observed under microscope. Flow cytometry was performed to evaluate the cell apoptosis, cell cycle, the mitochondrial membrane potential and the intracellular accumulation of reactive oxygen species (ROS). The protein expression was respectively measured by flow cytometry and western blotting.
RESULTS
RESULTS
DSF or DSF/Cu exhibited a marked inhibitory effect on the growth of DLBCL cells, accompanied by cell cycle arrest at the G0/G1 phase. Meanwhile, DSF or DSF/Cu significantly induced DLBCL cells apoptosis. Further study revealed that DSF or DSF/Cu promoted apoptosis by inhibiting NF-κB signaling pathway. Interestingly, DSF/Cu significantly reduced BCL6 and AIP levels. In addition, DSF significantly up-regulate p53 protein in OCI-LY7 and OCI-LY10 while down-regulate p53 protein in OCI-LY1 and U2932.
CONCLUSION
CONCLUSIONS
These results provided evidence for the anti-lymphoma effects of DSF on DLBCL and suggested that DSF has therapeutic potential to DLBCL.
Identifiants
pubmed: 35883106
doi: 10.1186/s12935-022-02661-4
pii: 10.1186/s12935-022-02661-4
pmc: PMC9317061
doi:
Types de publication
Journal Article
Langues
eng
Pagination
236Subventions
Organisme : Natural Science Foundation of Zhejiang
ID : Y18H200014
Informations de copyright
© 2022. The Author(s).
Références
Balkan Med J. 2021 Dec 20;39(1):30-38
pubmed: 34928233
Blood. 2016 Aug 4;128(5):660-6
pubmed: 27166359
Immunol Rev. 2012 May;247(1):172-83
pubmed: 22500840
Bone Marrow Transplant. 2016 Jan;51(1):51-7
pubmed: 26367239
Br J Cancer. 2011 May 10;104(10):1564-74
pubmed: 21487404
Cell. 2017 Oct 5;171(2):481-494.e15
pubmed: 28985567
Front Cell Dev Biol. 2019 Nov 07;7:272
pubmed: 31788471
Leuk Lymphoma. 2014 Feb;55(2):425-34
pubmed: 23721513
Blood. 2007 Sep 15;110(6):2067-74
pubmed: 17545502
Drug Discov Today. 2012 May;17(9-10):409-12
pubmed: 22192884
Nat Med. 2004 Dec;10(12):1329-35
pubmed: 15531890
Mol Pharm. 2004 Nov-Dec;1(6):426-33
pubmed: 16028354
Oncotarget. 2016 Jan 19;7(3):3520-32
pubmed: 26657288
Int J Biochem Cell Biol. 2020 Apr;121:105715
pubmed: 32035180
J Biol Chem. 2019 Jan 4;294(1):299-313
pubmed: 30409904
Int J Biochem Cell Biol. 2013 Jan;45(1):64-7
pubmed: 23064052
Leuk Lymphoma. 2002 Nov;43(11):2179-89
pubmed: 12533045
Trends Pharmacol Sci. 2019 Feb;40(2):128-141
pubmed: 30612715
N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
Haematologica. 2015 Jun;100(6):801-9
pubmed: 25769544
Oxid Med Cell Longev. 2016;2016:4350965
pubmed: 26998193
Clin Cancer Res. 2016 Aug 1;22(15):3860-75
pubmed: 27006494
Blood. 2013 Jan 10;121(2):278-85
pubmed: 23149845
Inflammopharmacology. 2018 Oct;26(5):1265-1272
pubmed: 29644554
Mol Oncol. 2015 Jun;9(6):1155-68
pubmed: 25769405
J Nanobiotechnology. 2016 Apr 21;14:32
pubmed: 27102110
Oncotarget. 2016 Dec 13;7(50):82200-82212
pubmed: 27203215
J Cancer Res Clin Oncol. 2016 Mar;142(3):561-72
pubmed: 26498772
J Pathol. 2008 Mar;214(4):498-507
pubmed: 18189332
Cell Death Dis. 2017 May 18;8(5):e2797
pubmed: 28518151
Cancer Cell. 2018 Sep 10;34(3):453-465.e9
pubmed: 30205047
Immunity. 2000 Aug;13(2):199-212
pubmed: 10981963
J Nucl Med. 2013 Jun;54(6):953-60
pubmed: 23616582
Br J Cancer. 2012 Oct 23;107(9):1488-97
pubmed: 23033007
Cell Rep. 2019 Apr 30;27(5):1461-1471.e4
pubmed: 31042473
Cancer Res. 2010 Mar 15;70(6):2516-27
pubmed: 20215516
Immunity. 2009 Sep 18;31(3):457-68
pubmed: 19631565
Immunotherapy. 2019 Mar;11(4):265-272
pubmed: 30606076
Hematol Oncol. 2019 Oct;37(4):333-344
pubmed: 30938848
Cell Rep. 2013 Aug 15;4(3):578-88
pubmed: 23911289
J Immunol. 2013 Oct 1;191(7):3705-11
pubmed: 23980208
Clin Pharmacol Ther. 1984 Oct;36(4):520-6
pubmed: 6090051
Cancers (Basel). 2020 Nov 27;12(12):
pubmed: 33260923
Cell Death Dis. 2017 Jun 22;8(6):e2890
pubmed: 28640256
Drug Discov Today. 2020 Jun;25(6):1099-1108
pubmed: 32320854
Br J Haematol. 2013 Sep;162(5):621-30
pubmed: 23795761
Onco Targets Ther. 2020 Oct 15;13:10475-10487
pubmed: 33116627
Rinsho Byori. 2012 Jun;60(6):550-2
pubmed: 23061109
Cell Mol Life Sci. 2020 Nov;77(22):4459-4483
pubmed: 32358622
Aging (Albany NY). 2016 Dec 8;8(12):3321-3340
pubmed: 27941215
Semin Cancer Biol. 2016 Aug;39:26-31
pubmed: 27546290
Blood. 2006 Feb 15;107(4):1599-607
pubmed: 16249378